Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von BioPharma Dive

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
DoBristol Myers says schizophrenia drug launch 'off to a solid start'
DoMerck takes $200M tariff hit, trimming its gross profits
DoSanofi stays course amid tariff turmoil
DoVersant startup Granite debuts with $100M and two immune drugs
DoEtiome, a new Flagship startup, looks to catch disease before it strikes
Mi[Podcast] Behind the Breakthroughs: How Almac Powers Clinical Trial Success with Care
MiGerman antibody maker Veraxa Biotech valued at $1.6B in blank-check merger
MiBristol Myers' prized schizophrenia drug stumbles in testing
MiRoche looks to a Flagship startup in search of new immune drugs
DiRoche, answering tariff threat, pledges $50B to US drug production
DiFormer Neumora CEO to lead Galapagos spinout
DiThe Trump administration is remaking HHS. Track the changes here.
DiArkansas passes law banning PBMs from owning pharmacies
MoNovo says it's submitted obesity pill for FDA approval
MoEnhertu combo tops standard drugs in first-line HER2 breast cancer
18.04.An investment fund sets out to free biotech's 'trapped capital'
18.04.Sanofi, Regeneron win FDA nod for Dupixent in chronic hives
18.04.Makary seeks to limit industry's role in FDA advisory panels
18.04.GSK prepares to relaunch Blenrep; Activists challenge another 'zombie' biotech
18.04.FDA cuts outlined in draft HHS budget
17.04.Lilly's obesity pill scores in large diabetes trial
17.04.Sanofi licenses immune disease drugs from startup Earendil
17.04.A judge blocked the FDA's plan to regulate lab developed tests. What now?
17.04.CDC panel backs broader use of RSV shots
16.04.Bluebird says Ayrmid missed deadline for rival takeover bid